Shares of Anuh Pharma have rallied by 7% to Rs 352, extending their previous day’s over 15% surge on the BSE, after the stock turned ex-bonus on Wednesday, August 5, 2015.
The bulk drug manufacturer has fixed August 06, 2015 as the record date for the purpose of issuing bonus shares in the ratio of 2:1 i.e. two equity shares of face value of Rs 5 each for every one equity share of face value of Rs 5 each.
The stock touched a record high of Rs 356 in intra-day trades today, zooming by 26% in the past two trading sessions from Rs 282 (adjusted to bonus issue) on August 4.
Anuh Pharma is a debt-free company with revenues growing at a compound annual growth rate (CAGR) of 10% over the past 5 years.
The company said that it expects to significantly increase its market share on corticosteroids as well in the next couple of years, given the low base.
“The company’s immediate focus shall be on exploiting the current product approvals in Europe which offer a US $15 million opportunity; more approvals are pending which will enhance this addressable market further,” Anuh Pharma said in a investor presentation.
The three new products proposed for FY16 launch are in anti-bacterial and respiratory segments, Anuh Pharma added.
The bulk drug manufacturer has fixed August 06, 2015 as the record date for the purpose of issuing bonus shares in the ratio of 2:1 i.e. two equity shares of face value of Rs 5 each for every one equity share of face value of Rs 5 each.
The stock touched a record high of Rs 356 in intra-day trades today, zooming by 26% in the past two trading sessions from Rs 282 (adjusted to bonus issue) on August 4.
Anuh Pharma is a debt-free company with revenues growing at a compound annual growth rate (CAGR) of 10% over the past 5 years.
The company said that it expects to significantly increase its market share on corticosteroids as well in the next couple of years, given the low base.
“The company’s immediate focus shall be on exploiting the current product approvals in Europe which offer a US $15 million opportunity; more approvals are pending which will enhance this addressable market further,” Anuh Pharma said in a investor presentation.
The three new products proposed for FY16 launch are in anti-bacterial and respiratory segments, Anuh Pharma added.